Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

n. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II. Angiotensin II is a small peptide in the body and part of the so-called renin-angiotensin system (RAS), an important regulator of blood pressure. Angiotensin II causes blood vessels to narrow,
resulting in increased blood pressure. In a phase IIa clinical trial, vaccination with CYT006-AngQb has been shown to reduce blood pressure by induction of antibodies that bind angiotensin II. Thereby, binding of angiotensin II to its receptors and subsequent narrowing of blood vessels should be decreased. The RAS has already been successfully targeted by three major classes of antihypertensive drugs on the market: inhibitors of the angiotensin-converting-enzyme (ACE), antagonists of the angiotensin II type I receptor (ARBs) and renin inhibitors. Like other antihypertensive drugs these also come with the need for daily dosing and fail to provide a solution for improving patient compliance. Treatment with CYT006-AngQb should allow for convenient dosing schedules and smooth control of blood pressure due to a sustained antibody response induced by vaccination.



About Cytos Biotechnology AG
Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the ImmunodrugsTM. ImmunodrugsTM are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. ImmunodrugsTM are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its ImmunodrugTM platform, Cytos Biotechnology has built a pipeline of different ImmunodrugTM candidates in various disease areas, of which 6 are currently in clinical development. The Imm
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:3/2/2015)... , March 2, 2015 Valencia Technologies Corporation ... patient with its radically small device for the ... early results in this randomized, double-blinded, controlled trial are ... of confidence that it will succeed in a large ... early clinical results, Valencia has ...
(Date:3/2/2015)... 2015 Following announcements from both Novartis ... BioPharma Inc. (NASDAQ:  ARRY) today announced the completion ... with Novartis.  Along with global ownership of both ... $85 million from Novartis. Ron Squarer, ... of the Novartis-GSK transaction, Array now owns both ...
(Date:3/2/2015)... , March 2, 2015  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced that Josh Blacher , ... the 27th Annual ROTH conference in Laguna ... at 2:30 PM Pacific Standard Time. A live webcast ...
Breaking Medicine Technology:Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5Galmed Pharmaceuticals to Present at the 27th Annual ROTH Conference 2
... , SAN ... marketer of the VerifyNow® System, the first rapid and easy-to-use ... agents (e.g. Plavix® and aspirin), announced today that Timothy I. ... Chief Financial Officer of Accumetrics, will be presenting a corporate ...
... , RALEIGH, N.C., Nov. 24 ... for the pharmaceutical and biotech industry, today announced the launch ... The new Hospital Marketplace e-course is the newest ... a comprehensive series of e-courses designed to fill the critical ...
Cached Medicine Technology:Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 3
(Date:3/1/2015)... Women’s Excellence is pleased to announce the addition of ... There are over 75 terms and phrases available for viewing, ... gives our patients a better understanding of what our Providers are ... understand. With this resource, our patients are able to go ... and phrases that they may not remember or comprehend at the ...
(Date:3/1/2015)... York, NY (PRWEB) March 01, 2015 ... and seek insurance rates for term or universal policies ... of some of the best life insurance companies for ... through the system at http://quotespros.com/life-insurance.html . , The ... the search portal are tied to a number of ...
(Date:3/1/2015)... Ticket Down is a reputable source for authentic ... Deadheads have been anxiously anticipating this blockbuster weekend ever ... formed 50 years ago back in the 60s in Palo ... untimely death of Jerry Garcia in 1995. This beloved ... rock, bluegrass, folk, space rock and country to become an ...
(Date:3/1/2015)... 2015 ERISAPros is pleased ... Roddy to the professional staff of its Compliance Department. ... The Ohio State University-Mortiz College of Law. Prior to ... working with several Fortune 500 companies as well as ... corporate benefits. Her experiences range from benefit plan design, ...
(Date:3/1/2015)... 2015 CrossFit Attollo is a CrossFit gym ... a special discount to new members. Now through the ... three month contract will receive their fourth month half off. ... members $440. The three month contract is only $264, ... the fourth month comes in at only $55. The special ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2
... Canadian researchers report , , FRIDAY, July 18 (HealthDay News) -- ... but researchers report they have been able to do that ... pulses into the brain. , Someone with lazy eye -- ... eye is weaker than the other. Early treatment often has ...
... McCain Is Not What America Signed Up For, ... advisor, Phil Gramm, echoed McCain,s comments that America,s,economic problems ... and that America had become a "nation of whiners." ... is now back on board as,McCain,s top economic adviser. ...
... by a Michigan State University scholar refutes commonly held ... and harder to get along with than their "normal ... to guard against the use of weight-based stereotypes when ... Roehling, associate professor of human resource management, and two ...
... Calif., July 18 Actress and best-selling author,Jenny ... in the search,for an autism cure and advocate ... McCarthy incorporated the Global Health Trax(TM) (GHT) flagship,specialty ... and shared her experience in her book Louder ...
... ease symptoms, but old drug offers new hope , , FRIDAY, ... one step back in the search for treatments against Alzheimer,s ... 19 issue of The Lancet , an older drug ... report, a once-promising vaccine failed to prevent the progression of ...
... Cites Work with Women Veterans, WASHINGTON, July 18 ... Center for Post Traumatic,Stress Disorder (PTSD), received the 3rd ... with PTSD and women veterans., "Dr. Schnurr,s contribution ... to healing those who have borne the battle,",said Secretary ...
Cached Medicine News:Health News:Magnetic Pulses to Brain Improve Lazy Eye in Adults 2Health News:Magnetic Pulses to Brain Improve Lazy Eye in Adults 3Health News:DNC: McCain Watch: The Economy 2Health News:DNC: McCain Watch: The Economy 3Health News:Studies refute common stereotypes about obese workers 2Health News:Global Health Trax Joins Fight Against Autism With Jenny McCarthy and Generation Rescue 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4
The VPAP III is a complete system solution for sleep-disordered breathing (SDB), providing comfortable and effective bilevel treatment. The VPAP III is an effective business solution for clinicians, ...
... for the Separation and Measurement of ... Subfractions, ,The Lipoprint System is a ... components which are not routinely tested ... provides detailed results within the subfractions ...
... high resolution diagnostic test for cholesterol components which ... test procedure is simple and can be done ... is clearly flagged. A color coded profile is ... in red and the good HDL in green. ...
... Ammonia/Alcohol Control is intended as ... ammonia and ethanol assay methods. ... targeted at clinically significant levels ... values are provided for the ...
Medicine Products: